Durgical
EN
Open the app

Ovarian cancer: spread, staging and treatment in outline

  • Disorder

Ovarian cancer whispers: bloating and feeling full early. Most women are diagnosed late, and survival depends on a specialist removing every visible tumour.

Updated

See it in 3D: Ovaries · Uterine tubes · Infundibulum and fimbriae · Rectouterine pouch · External iliac nodes

What it is

Most ovarian cancers are epithelial; the commonest and most lethal, high-grade serous carcinoma, usually starts in the fimbrial end of the fallopian tube. Other epithelial types are low-grade serous, endometrioid and clear cell (both linked to endometriosis) and mucinous; younger women more often have germ cell tumours, and sex cord–stromal tumours can make hormones. Epithelial cancer spreads mainly by shedding cells into the peritoneal fluid, so it coats the peritoneum, omentum and diaphragm and causes ascites, and also through the lymph nodes. It is staged surgically (FIGO I to IV) and most women present at stage III. Treatment combines cytoreductive surgery by a gynaecological oncologist, aiming for no visible residual disease, with platinum and taxane chemotherapy and, in selected women, maintenance with PARP inhibitors or bevacizumab.

How to recognise it

  • Symptoms are persistent and new: bloating, early satiety, abdominal or pelvic pain and urinary urgency or frequency, most days for weeks.
  • Examination may find a fixed pelvic mass, ascites or an omental mass; a pleural effusion can be the first sign.
  • CA-125 and ultrasound help to assess a mass (a risk of malignancy index combines them with menopausal status) but do not work as population screening.
  • Germline BRCA1 or BRCA2 variants and Lynch syndrome raise the risk; every woman with epithelial ovarian cancer should be offered genetic testing.
  • Young woman with a solid mass: measure AFP, hCG and LDH for germ cell tumours.

FIGO staging in outline and what it means

StageExtentWhat it means
ILimited to one or both ovaries or tubes (with capsule rupture or cells in washings as substages)Often found by chance; surgery with full staging, chemotherapy for higher-risk types
IISpread within the pelvis (uterus, other adnexa, pelvic peritoneum)Surgery and chemotherapy
IIIPeritoneum outside the pelvis and/or retroperitoneal lymph nodesThe commonest stage at diagnosis; cytoreduction and chemotherapy, maintenance in selected women
IVDistant: malignant pleural effusion, liver or spleen parenchyma, organs outside the abdomenChemotherapy first, interval surgery if a complete resection becomes possible

Differential and risks

  • Differential of a pelvic mass with ascites: benign ovarian tumours (fibroma with ascites), tuberculous peritonitis, liver cirrhosis with an incidental cyst, and gastrointestinal cancers spreading to the ovaries (Krukenberg tumours).
  • Primary cytoreduction aims to remove all visible disease; when this is not possible, chemotherapy is given first and interval surgery follows (neoadjuvant approach).
  • Standard chemotherapy is carboplatin with paclitaxel; recurrence is common, and the time since the last platinum guides what comes next.
  • PARP inhibitors as maintenance prolong remission most in women with BRCA variants or homologous recombination deficiency.
  • Complications: bowel obstruction, recurrent ascites and pleural effusions, thrombosis; early palliative care improves quality of life.

Next step / Initial management

  • Suspected cancer: transvaginal and abdominal ultrasound, CA-125 (and AFP, hCG, LDH in young women), and CT of chest, abdomen and pelvis.
  • Refer every suspicious mass to a gynaecological oncology team before surgery: outcomes are better when the first operation is done by a specialist.
  • Offer germline BRCA and other genetic testing to every woman with epithelial ovarian cancer, and cascade testing to her relatives.
  • Prevention: risk-reducing removal of tubes and ovaries for BRCA carriers once childbearing is complete; removing the tubes at other pelvic surgery may lower risk in the general population.
  • Do not screen average-risk women with CA-125 or ultrasound: it does not reduce deaths and leads to unnecessary surgery.

Common traps

  • Bloating and early satiety in a woman over 50 are a bowel problem: persistent symptoms like these are the typical early presentation of ovarian cancer, so examine her and measure CA-125 before calling it irritable bowel.
  • Operating on a suspicious mass in a general unit and leaving disease behind: residual tumour is the strongest surgical predictor of survival.
  • Expecting CA-125 to work as a screening test: it rises with endometriosis, fibroids, pregnancy and peritoneal irritation, and misses many early cancers.
  • Thinking a negative family history makes BRCA testing pointless: many carriers have no known affected relatives.

Test yourself

Think of the answer, then tap the question to see it.

A 60-year-old has two months of bloating, early satiety and urinary frequency. What should you do?

Examine her abdomen and pelvis and arrange a pelvic ultrasound and CA-125; persistent new symptoms like these can be ovarian cancer.

Why does advanced ovarian cancer typically involve the omentum and the right diaphragm?

It spreads by shedding cells into the peritoneal fluid, which circulates up the right side to the diaphragm and collects in the omentum.

Why should every woman with epithelial ovarian cancer be offered BRCA testing?

Many carriers have no family history; a positive result guides maintenance with PARP inhibitors and allows relatives to be tested and offered prevention.

Add to my cards (3)

Elsewhere in DurgiPedia

Connections

← All of obstetrics and gynaecology

Educational content; it does not replace assessment by a doctor or your institution's protocols, and it contains no doses. For heavy bleeding, a severe headache or blurred vision, a seizure, fever, strong abdominal pain or fewer baby movements, go to an emergency department at once.

Sources: Epithelial Ovarian Cancer (StatPearls Publishing (NCBI Bookshelf), 2024); Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®), health professional version (National Cancer Institute, 2025); BRCA1 and BRCA2 Mutations (StatPearls Publishing (NCBI Bookshelf), 2023).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.